Bank Julius Baer & Co
ALNY icon

Bank Julius Baer & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank Julius Baer & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98M Buy
16,575
+3,294
+25% +$994K 0.01% 256
2026
Q1 		$4.26M Buy
+13,281
New +$4.52M 0.01% 249
2024
Q1 		– Sell
-4,572
Closed -$875K – 528
2023
Q4 		$875K Buy
+4,572
New +$779K ﹤0.01% 292

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank Julius Baer & Co's ALNY Position: Q2 2026 in Review

Bank Julius Baer & Co increased its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q2 2026, buying an estimated $994K and bringing the position to 16,575 shares worth $4.98M. The position accounts for 0.01% of the portfolio, ranked #256.

Bank Julius Baer & Co first reported a position in ALNY in Q4 2023 and has held it in 3 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bank Julius Baer & Co held 16,575 shares of Alnylam Pharmaceuticals worth $4.98M as of Q2 2026.
  • Bank Julius Baer & Co bought 3,294 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $994K.
  • Alnylam Pharmaceuticals made up 0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #256 holding.
  • Bank Julius Baer & Co first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.